Isoai A, Goto-Tsukamoto H, Yamori T, Oh-hara T, Tsuruo T, Silletti S, Raz A, Watanabe H, Akedo H, Kumagai H
Research Center, Asahi Glass Co., Ltd., Yokohama, Japan.
Cancer Res. 1994 Mar 1;54(5):1264-70.
Tumor invasion-inhibiting factor 2 (IIF-2) is a polypeptide of 21 amino acids which binds to the surface of tumor cells and inhibits experimental invasion in vitro. An albumin conjugate of IIF-2 was used to examine its potential as an antimetastatic compound. The conjugate inhibits in vivo lung metastasis of various highly metastatic tumor cells, including murine melanoma, colon adenocarcinoma, squamous cell carcinoma, forestomach carcinoma, and human fibrosarcoma. In addition to the anti-lung metastasis activity of this compound, it also showed the inhibitory effects on liver and spleen metastasis of murine T-lymphoma cells. A single administration of the conjugate with melanoma cells resulted in prolonged survival times, and their lung colonization was also inhibited when the conjugate was administrated i.v. at times ranging from 6 h before to 1 h after tumor cell inoculation. Similarly, i.p. administration 1 h prior to melanoma cell injection suppressed lung colonization. Pharmacokinetic analysis revealed that the conjugate was more stable than IIF-2 peptide alone. Approximately 10% of the conjugate remained circulating 2 h postinjection and persisted 20 h without degradation, compared with rapid clearing of the unconjugated IIF-2 peptide within 5 min. Furthermore, spontaneous lung metastasis of murine melanoma and colon adenocarcinoma cell was inhibited by successive i.p. administration of the conjugate before the removal of the primary site, with no effect on primary tumor growth. The conjugate significantly reduced tumor cell arrest in the lung and both the IIF-2 peptide and its conjugate demonstrated potent inhibition of basal as well as cytokine-induced-stimulated tumor cell motility. These results suggest that one mode of IIF-2 action may be inhibition of the extravasation of metastasizing cells which have arrested in a target organ, and that the IIF-2-albumin conjugate may be a potent antimetastatic substance with utility in the prevention of artificial seeding of tumor cells during surgical removal of the primary lesions as well as inhibiting metastasis from established metastases.
肿瘤侵袭抑制因子2(IIF - 2)是一种由21个氨基酸组成的多肽,它能与肿瘤细胞表面结合并在体外抑制实验性侵袭。IIF - 2的白蛋白缀合物被用于研究其作为抗转移化合物的潜力。该缀合物可抑制多种高转移性肿瘤细胞在体内的肺转移,包括小鼠黑色素瘤、结肠腺癌、鳞状细胞癌、前胃癌和人纤维肉瘤。除了这种化合物的抗肺转移活性外,它还对小鼠T淋巴瘤细胞的肝转移和脾转移显示出抑制作用。将缀合物与黑色素瘤细胞单次给药可延长存活时间,并且当在肿瘤细胞接种前6小时至接种后1小时的时间段内静脉注射缀合物时,其肺部定植也受到抑制。同样,在黑色素瘤细胞注射前1小时腹腔注射也可抑制肺部定植。药代动力学分析表明,该缀合物比单独的IIF - 2肽更稳定。注射后2小时,约10%的缀合物仍在循环,并且持续20小时未降解,相比之下,未缀合的IIF - 2肽在5分钟内迅速清除。此外,在切除原发部位之前连续腹腔注射缀合物可抑制小鼠黑色素瘤和结肠腺癌细胞的自发性肺转移,而对原发肿瘤生长无影响。该缀合物显著减少了肿瘤细胞在肺部的滞留,并且IIF - 2肽及其缀合物均显示出对基础以及细胞因子诱导刺激的肿瘤细胞运动的有效抑制。这些结果表明,IIF - 2的一种作用模式可能是抑制已在靶器官滞留的转移细胞的外渗,并且IIF - 2 - 白蛋白缀合物可能是一种有效的抗转移物质,可用于在手术切除原发病变期间预防肿瘤细胞的人工播种以及抑制已形成转移灶的转移。